Tag: DurAVR transcatheter heart valve
$38.5M investment to expand Anteris’ manufacturing capacity, global clinical program
Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
Manufacturers should do this sooner rather than later, says precision engineer
Australian precision engineering and industrial instrumentation company CENMAC implemented ERP software when it was still a one-man operation. “I couldn’t imagine us growing to this size without MRPeasy,” says Jason Ford, Founder.
